Pia intervjuade chefsanalytiker Antti Siltanen och de diskuterade självklart detta företag. We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is all about, competing drug candidates and other pressing questions regarding the company. Inderes Herantis Pharma: Disease-modifying drug for Parkinson’s - Inderes Time: 2024-06-26 11:53 We have initiated coverage of Herantis Pharma, a drug development company focused on neurodegenerative diseases. In this interview analyst Antti Siltanen sheds light on what the company does, what its drug candidate HER-096 is... Content: 00:00 Intro 00:16 What does Herantis do? 00:52 How does HER-096 work? 01:20 Risks 03:19 Competing drug candidates 04:57 Capital adequacy and funding options 06:23 Probability of commercialization 07:12 When to expect profit generation?

Herantis Pharma är ett finländskt bioteknikföretag som specialiserar sig på läkemedelsforskning och utvecklar behandlingar för flera sjukdomar, såsom Parkinsons sjukdom, skleros och bröstcancer. Företaget har en bred produktportfölj i olika kliniska faser. Herantis Pharma bildades genom en sammanslagning av Hermo Pharma och Laurantis Pharma och har sitt huvudkontor i Esbo. Många har säkert höga förväntningar på det här företaget. Visst finns det risker, men också stor potential. Jag behöver inte berätta mer om företaget eftersom en av Inderes’ bästa aktieanalytiker har gjort en ny utmärkt och lättläst analys av företaget, där du hittar all eller nästan all information du söker om företaget. Här är analysen gjord av analytikern @antti.siltanen: Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson’s disease. The risk level of the stock as an investment is very high, as the likelihood of successful drug development is still low due to the early development phase. As a counterbalance, the market for Parkinson’s disease is large and no disease-modifying drugs are available yet. Our DCF model suggests that the stock is attractively priced. Value creation can also materialize through a development and commercialization agreement or an acquisition. We initiate coverage with an Accumulate recommendation and a target price of EUR 2.2. Inderes Herantis Pharma initiation of coverage: Early stage drug development requires... Herantis is a drug development company focused on neurodegenerative diseases. Herantis currently has one candidate in the clinical Phase I, HER-096, which the company develops as a disease-modifying drug for Parkinson's disease.

New series of articles! We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug. Inderes Clinical phases of drug development - Inderes We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they...